Testing ctDNA to start elacestrant in early breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You were diagnosed with stage IIB or III ER+/HER2- breast cancer at least 5 years ago (but no more than 20 years ago).
- You have completed at least 5 years of hormone therapy (like tamoxifen or an aromatase inhibitor) and stopped it at least 4 weeks ago.
- A blood test shows you have circulating tumor DNA (ctDNA), which may mean there's a small amount of cancer cells still present.
- You have no signs of cancer spread on CT or other scans.
- You are willing to have a bone marrow or organ function check that meets certain lab targets.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called elacestrant for advanced breast cancer that is triple-positive (positive for three hormone receptors: ER, PR, and HER2). The drug may help slow or shrink cancer that has progressed despite previous treatments.
This trial tests a new combination of two targeted drugs (elacestrant and Enhertu) for people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultra-low) that did not respond to standard treatments like CDK4/6 inhibitors. The goal is to see if this combination works better than current options.
This trial tests a new hormone therapy (elacestrant) alone or combined with a targeted pill (abemaciclib) for people with advanced or recurrent endometrial cancer that is hormone-receptor-positive. The goal is to see if these treatments can shrink tumors or slow the cancer's growth.
This trial tests whether elacestrant, a drug that blocks estrogen, can help people with certain types of uterine sarcoma that have strong estrogen receptors. It may slow or stop cancer growth in tumors that rely on estrogen.
This trial tests whether elacestrant can help stop or delay breast cancer coming back in people whose blood test shows “ctDNA relapse” after early breast cancer treatment. It’s meant for hormone receptor–positive, HER2-negative breast cancer patients who are already taking hormone (endocrine) therapy and have no visible spread on scans.
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Hear when a new ER+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.